NCT02244463View on ClinicalTrials.gov

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Anaplastic Thyroid CancerThyroid CancerDifferentiated Thyroid Cancer
Interventions
DRUG

MLN0128

Trial Locations (3)

48109

University of Michigan Medical School, Ann Arbor

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER